Cited by 111Diabetes and associated disordersPancreatic function and diabetesDiabetes Management and Research

Absence of islet autoantibodies and modestly raised glucose values at diabetes diagnosis should lead to testing for MODY: lessons from a 5-year pediatric Swedish National Cohort Study

Open access
Carlsson, Annelie, Shepherd, Maggie, Ellard, Sian, Weedon, Michael, Lernmark, Åke, Forsander, Gun, Colclough, Kevin, Brahimi, Qefsere +9 more·2020·Diabetes Care

Abstract

OBJECTIVE: Identifying maturity-onset diabetes of the young (MODY) in pediatric populations close to diabetes diagnosis is difficult. Misdiagnosis and unnecessary insulin treatment are common. We aimed to identify the discriminatory clinical features at diabetes diagnosis of patients with glucokinase (GCK), hepatocyte nuclear factor-1A (HNF1A), and HNF4A MODY in the pediatric population. RESEARCH DESIGN AND METHODS: Swedish patients (n = 3,933) aged 1–18 years, diagnosed with diabetes May 2005 to December 2010, were recruited from the national consecutive prospective cohort Better Diabetes Diagnosis. Clinical data, islet autoantibodies (GAD insulinoma antigen-2, zinc transporter 8, and insulin autoantibodies), HLA type, and C-peptide were collected at diagnosis. MODY was identified by sequencing GCK, HNF1A, and HNF4A, through either routine clinical or research testing. RESULTS: The minimal prevalence of MODY was 1.2%. Discriminatory factors for MODY at diagnosis included four islet autoantibody negativity (100% vs. 11% not-known MODY; P = 2 × 10−44), HbA1c (7.0% vs. 10.7% [53 vs. 93 mmol/mol]; P = 1 × 10−20), plasma glucose (11.7 vs. 26.7 mmol/L; P = 3 × 10−19), parental diabetes (63% vs. 12%; P = 1 × 10−15), and diabetic ketoacidosis (0% vs. 15%; P = 0.001). Testing 303 autoantibody-negative patients identified 46 patients with MODY (detection rate 15%). Limiting testing to the 73 islet autoantibody-negative patients with HbA1c <7.5% (58 mmol/mol) at diagnosis identified 36 out of 46 (78%) patients with MODY (detection rate 49%). On follow-up, the 46 patients with MODY had excellent glycemic control, with an HbA1c of 6.4% (47 mmol/mol), with 42 out of 46 (91%) patients not on insulin treatment. CONCLUSIONS: At diagnosis of pediatric diabetes, absence of all islet autoantibodies and modest hyperglycemia (HbA1c <7.5% [58 mmol/mol]) should result in testing for GCK, HNF1A, and HNF4A MODY. Testing all 12% patients negative for four islet autoantibodies is an effective strategy for not missing MODY but will result in a lower detection rate. Identifying MODY results in excellent long-term glycemic control without insulin.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc19-0747

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Mutational analyses are established for classification of diabetes in the neonate as well as in young individuals with a dominant family history of diabetes (MODY).

    “However, an exception is the mutational analyses established for classification of diabetes in the neonate (381-384) as well as in young individuals with a dominant family history of diabetes, often referred to as maturityonset diabetes of the young (MODY) (384,385) (Table 8).”
  • At diagnosis of diabetes in children, absence of all four islet autoantibodies and modest hyperglycemia (HbA1c <7.5% [58 mmol/mol]) proved useful for the detection of MODY.

    “At diagnosis of diabetes in children, absence of all four islet autoantibodies and modest hyperglycemia (HbA 1c <7.5% [58 mmol/mol]) proved useful for the detection of MODY (384).”
  • Infants with neonatal diabetes due to a mutation in the KCNJ11 (Kir6.2) gene may be treated with a sulfonylurea rather than with insulin.

    “For example, infants with neonatal diabetes due to a mutation in the KCNJ11 (Kir6.2) gene may be treated with a sulfonylurea rather than with insulin (382,384,398).”

    From Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus (2023) · cites this paper as [384]

    The Introduction and Results discuss sulphonylurea treatment for HNF1A and HNF4A MODY, not KCNJ11-related neonatal diabetes. Searches for KCNJ11/Kir6.2 and neonatal diabetes found no passage in our copy addressing whether affected infants can use a sulfonylurea instead of insulin. (LLM, conf=0.77)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

2 of the 34 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Carlsson, A., Shepherd, M., Ellard, S., Weedon, M., Lernmark, Å., Forsander, G., Colclough, K., Brahimi, Q., Valtonen-Andre, C., Ivarsson, S. A., Elding Larsson, H., Samuelsson, U., Örtqvist, E., Groop, L., Ludvigsson, J., Marcus, C., & Hattersley, A. T.
Affiliations
  • Lund University (SE)
  • University of Exeter (GB)
  • Sahlgrenska University Hospital (SE)
  • Royal Devon & Exeter NHS Foundation Trust (GB)
  • Department of Clinical Chemistry, University and Regional Laboratories Region Skåne, Malmö, Sweden
  • Department of Clinical Sciences, Lund University/Clinical Research Centre, Skåne University Hospital, Malmö, Sweden
  • Linköping University (SE)
  • Karolinska Institutet (SE)
  • University of Helsinki (FI)
Corresponding author
  • Marcus, Claude
  • Hattersley, Andrew T.
Venue
Diabetes Care
Published
2019-12-12
Volume
43
Issue
1
Pages
82-89
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2986370305
Cited by
111
References
34
Citations by year
2026: 11 · 2025: 14 · 2024: 16 · 2023: 19 · 2022: 24 · 2021: 15 · 2020: 12
FWCI
7.68
Type
journal article
Language
en
Open access
Locations
  • Diabetes Care (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Open Research Exeter (University of Exeter) (acceptedVersion)
  • Figshare (submittedVersion)
  • Työväentutkimus Vuosikirja (submittedVersion, other-oa)
  • Lund University Publications (Lund University) (submittedVersion)
  • Royal Devon and Exeter Research Repository (Royal Devon and Exeter) (submittedVersion)
Funders
  • Royal Devon and Exeter NHS Foundation Trust
  • Wellcome Trust (098395/Z/12/Z)
  • National Institute for Health and Care Research (NF-SI-0611-10219, NF-SI-0616-10080)
  • Lunds Universitet
  • Linköpings Universitet
  • National Institutes of Health
  • National Institute of Diabetes and Digestive and Kidney Diseases (UC4DK063861, U01DK063861)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
  • Health Sciences › Medicine › Surgery › Pancreatic function and diabetes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
maturity-onset diabetes of the young, pediatric diabetes, islet autoantibodies, glucokinase, HNF1A, HNF4α, diabetes misdiagnosis, HbA1c, plasma glucose, glycemic control, genetic testing, parental diabetes, diabetic ketoacidosis, C-peptide
MeSH terms
Adolescent, Autoantibodies, Blood Glucose, Child, Child, Preschool, Diabetes Mellitus, Type 2, Diagnosis, Differential, Female, Humans, Hyperglycemia, Infant, Islets of Langerhans, Male, Sweden, Cohort Studies, Prevalence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review